Core Viewpoint - Shanghai Yizhong (688091.SH) reported significant growth in its 2025 financial performance, driven by the inclusion of its core product, paclitaxel polymer micelles, in the national medical insurance catalog [1] Financial Performance - The company achieved an operating revenue of 317 million yuan in 2025, representing a year-on-year increase of 82.72% [1] - The net profit attributable to the parent company was 64.132 million yuan, showing a remarkable year-on-year growth of 819.42% [1] Product Impact - The inclusion of paclitaxel polymer micelles in the national medical insurance catalog significantly boosted market access and the number of patients using the product, contributing to the overall revenue and profit growth for the year [1]

Core Viewpoint - The 2025 performance forecasts for companies listed on the Sci-Tech Innovation Board show promising results, with nearly 250 companies disclosing their earnings, and around 50% of them expected to be profitable, indicating a recovery in market demand and growth in emerging industries such as semiconductors, biomedicine, and artificial intelligence [1] Group 1: Company Performance - 125 companies are expected to achieve profitability, with 67 companies forecasting positive growth in net profit year-on-year, and 29 companies anticipating a profit increase of over 100% [1][2] - Shanghai Yizhong leads with a projected net profit increase of 760.18% to 903.54%, followed by Zhenlei Technology and Baiwei Storage with expected increases of 529.64% to 642.26% and 427.19% to 520.22%, respectively [2] - Baiao Saitu anticipates a significant net profit increase of 384.26% to 443.88%, driven by its advanced antibody platform and collaborations with major companies [4] Group 2: Industry Trends - The semiconductor, biomedicine, and AI sectors are experiencing a surge in demand, contributing to the overall positive performance of the Sci-Tech Innovation Board companies [1][3] - Companies like Shijia Photon are benefiting from the AI boom, with a projected net profit increase of 425.95% due to rising orders in the data communication market [5] - The PCB and CCL industries are also seeing growth, with companies like Shengyi Electronics and Nanya New Materials expecting substantial profit increases due to high-quality orders and market expansion [6][7] Group 3: International Expansion - Many companies are actively pursuing international markets, with Pioneering Technology expecting a net profit of 62 million to 86 million yuan, a year-on-year increase of 50.82% to 109.21%, driven by international demand for energy storage solutions [3] - The internationalization strategy is becoming a key path for high-quality development among listed companies [3]

人民财讯1月21日电，上海谊众(688091)1月21日公告，预计2025年度实现归属于母公司所有者的净利润 为6000万元到7000万元，同比增长760.18%到903.54%。公司核心产品注射用紫杉醇聚合物胶束(简称"紫 杉醇胶束")于2025年正式纳入国家医保目录，在市场准入与用药人数上大幅提高，带动了公司全年营收 与利润相较于2024年显著增长。 ...

本期业绩变化的主要原因：公司核心产品注射用紫杉醇聚合物胶束(以下简称"紫杉醇胶束")于2025年正 式纳入国家医保目录，在市场准入与用药人数上大幅提高，带动了公司全年营收与利润相较于2024年显 著增长。 智通财经APP讯，上海谊众(688091.SH)发布2025年年度业绩预告公告，预计2025年度实现归属于母公 司所有者的净利润为6,000万元到7,000万元;与上年同期相比，增长760.18%到903.54%。 ...

南财智讯1月21日电，上海谊众发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 6000万元—7000万元，同比预增760.18%—903.54%；预计2025年全年归属于上市公司股东的扣除非经 常性损益的净利润为5600万元—6600万元，同比预增1338.87%—1595.81%，归属于上市公司股东的净 利润变动原因：公司核心产品注射用紫杉醇聚合物胶束（以下简称"紫杉醇胶束"）于2025年正式纳入国 家医保目录，在市场准入与用药人数上大幅提高，带动了公司全年营收与利润相较于2024年显著增长。 ...

Core Viewpoint - Shanghai Yizhong is facing significant performance pressure as its second-largest shareholder, Shanghai Kaibao, plans to reduce its stake amid high stock prices and declining earnings [2][9]. Shareholder Actions - On July 16, Shanghai Kaibao announced plans to sell up to 6.2011 million shares of Shanghai Yizhong, currently holding 24.7035 million shares, representing 11.95% of the company [2][4]. - This marks the second time Shanghai Kaibao has reduced its stake, having previously sold 1.0476 million shares in 2022 for approximately 97.2716 million yuan [2][8]. - As of July 17, Shanghai Yizhong's stock price was 67.9 yuan per share, reflecting a 70% increase year-to-date, with the current market value of Shanghai Kaibao's holdings around 1.677 billion yuan [4][9]. Company Performance - Shanghai Yizhong reported a revenue of 71.0322 million yuan in Q1 2025, a year-on-year increase of 3.39%, but net profit fell by 51.38% to 14.186 million yuan [3][10]. - The company experienced a significant decline in performance in 2024, with revenues dropping to 174 million yuan, a decrease of 51.83%, and net profit down 95.68% [10]. - The core product, paclitaxel micelles, was not included in the medical insurance directory until November 2024, impacting market access and sales performance [9][10]. Financial Metrics - In 2024, Shanghai Yizhong's sales and R&D expenses were 115 million yuan and 37.2037 million yuan, respectively, reflecting increases of 8.28% and 65.71% [10]. - For Q1 2025, sales and R&D expenses were 28.2088 million yuan and 9.2766 million yuan, accounting for 39.7% and 13.06% of total revenue [10].